Compile Data Set for Download or QSAR
Report error Found 128 Enz. Inhib. hit(s) with all data for entry = 10568
TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322074(1-{1-(cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy...)
Affinity DataKi:  0.340nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322125(US10183913, Example 447 | 1-(5-[(2,5-difluorobenzy...)
Affinity DataKi:  0.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322090(US10183913, Example 242 | US11576897, Example 242 ...)
Affinity DataKi:  0.520nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550841(US11312688, Example 400)
Affinity DataKi:  0.540nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322097(1-{5-[(2,5-difluorobenzyl)oxy]-1-(3-methylbutyl)-1...)
Affinity DataKi:  0.590nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550845(1-(2-{5-[(5-Chloro-2-fluorobenzyl)oxy]-3-[(methyla...)
Affinity DataKi:  0.600nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322094(1-{5-[(2,5-difluorobenzyl)oxy]-1-(2,2-dimethylprop...)
Affinity DataKi:  0.660nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322096(1-{5-[(2,5-difluorobenzyl)oxy]-1-(3,3-dimethylbuty...)
Affinity DataKi:  0.690nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322083(1-{1-(cyclopentylmethyl)-5-[(2,5-difluorobenzyl)ox...)
Affinity DataKi:  0.710nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322079(US10183913, Example 124 | US11576897, Example 124 ...)
Affinity DataKi:  0.710nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322132(US10183913, Example 481 | 1-{5-[(2,5-Difluorobenzy...)
Affinity DataKi:  0.850nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322103(US10183913, Example 288 | 1-[5-(Benzyloxy)-1-(1-cy...)
Affinity DataKi:  0.860nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322086(1-[5-(Benzyloxy)-1-(2-cyclopentylethyl)-1H-pyrazol...)
Affinity DataKi:  0.910nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322073(US10183913, Example 31 | 1-{1-(cyclohexylmethyl)-5...)
Affinity DataKi:  0.920nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322106(US10183913, Example 330 | 1-[5-(Benzyloxy)-1-(1-cy...)
Affinity DataKi:  0.960nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550837(1-{1-(Cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy...)
Affinity DataKi:  0.980nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322119(US10183913, Example 405 | US11312688, Example 426)
Affinity DataKi:  0.990nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322100(N-Methyl-1-{1-(3-methylbutyl)-5-[(2,4,5-trifluorob...)
Affinity DataKi:  1.10nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322107(US10183913, Example 331 | US11576897, Example 331 ...)
Affinity DataKi:  1.30nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322092(US10183913, Example 253 | US11312688, Example 253)
Affinity DataKi:  1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322077(US10183913, Example 115 | US11576897, Example 115 ...)
Affinity DataKi:  1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322072(US10183913, Example 5 | 1-[5-(benzyloxy)-1-(cycloh...)
Affinity DataKi:  1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550816(US11312688, Example 256)
Affinity DataKi:  1.60nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322088(1-{5-[(2,5-difluorobenzyl)oxy]-1-(4-fluorobenzyl)-...)
Affinity DataKi:  1.60nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322099(1-{1-(cyclopentylmethyl)-5-[(2,4,5-trifluorobenzyl...)
Affinity DataKi:  1.90nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322084(1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(cyclopentyl...)
Affinity DataKi:  1.90nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322076(US10183913, Example 108 | US11576897, Example 108 ...)
Affinity DataKi:  1.90nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322082(1-{1-(cyclopentylmethyl)-5-[(2,4-difluorobenzyl)ox...)
Affinity DataKi:  2.20nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550853(US11312688, Example 476)
Affinity DataKi:  2.30nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322089(1-{5-[(2,5-difluorobenzyl)oxy]-1-(4-methylbenzyl)-...)
Affinity DataKi:  2.30nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322095(1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(2,2-dimethy...)
Affinity DataKi:  2.40nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322133(US10183913, Example 482 | 1-{5-[(5-Chloro-2-fluoro...)
Affinity DataKi:  2.60nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322074(1-{1-(cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy...)
Affinity DataKi:  2.90nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322133(US10183913, Example 482 | 1-{5-[(5-Chloro-2-fluoro...)
Affinity DataKi:  2.90nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550835(1-{1-(Cyclohexylmethyl)-5-[difluoro(phenyl)methoxy...)
Affinity DataKi:  3nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550854(US11312688, Example 477)
Affinity DataKi:  3.10nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322117(US10183913, Example 381 | 1-{5-[(2-fluorobenzyl)ox...)
Affinity DataKi:  3.40nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322104(US10183913, Example 315 | 1-{1-(2-cyclopentylethyl...)
Affinity DataKi:  3.60nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550828(2-{5-(Benzyloxy)-3-[(methylamino)methyl]-1H-pyrazo...)
Affinity DataKi:  3.60nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322080(1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(cyclopropyl...)
Affinity DataKi:  3.70nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322126(US10183913, Example 448 | 1-(5-[(5-chloro-2-fluoro...)
Affinity DataKi:  3.80nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322086(1-[5-(Benzyloxy)-1-(2-cyclopentylethyl)-1H-pyrazol...)
Affinity DataKi:  3.90nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322091(US10183913, Example 248 | US11312688, Example 248)
Affinity DataKi:  4.30nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550845(1-(2-{5-[(5-Chloro-2-fluorobenzyl)oxy]-3-[(methyla...)
Affinity DataKi:  4.40nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322072(US10183913, Example 5 | 1-[5-(benzyloxy)-1-(cycloh...)
Affinity DataKi:  4.40nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322096(1-{5-[(2,5-difluorobenzyl)oxy]-1-(3,3-dimethylbuty...)
Affinity DataKi:  4.5nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322121(US10183913, Example 434 | US11312688, Example 434)
Affinity DataKi:  4.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322084(1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(cyclopentyl...)
Affinity DataKi:  4.60nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322083(1-{1-(cyclopentylmethyl)-5-[(2,5-difluorobenzyl)ox...)
Affinity DataKi:  4.80nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550798(US11312688, Example 42)
Affinity DataKi:  4.90nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

Displayed 1 to 50 (of 128 total ) | Next | Last >>
Jump to: